Tech Company Financing Transactions
Targacept Funding Round
Targacept, based in Winston-Salem, received $60 million from Nomura Phase4 Ventures, Advent International and Burrill & Company.
Transaction Overview
Company Name
Announced On
3/19/2003
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Proceeds Purpose
The $60 million raised in this round will allow the company to hit a number of key clinical milestones and will provide additional strategic flexibility.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 North Main St. 1510
Winston-Salem, NC 27101
USA
Winston-Salem, NC 27101
USA
Phone
Website
Email Address
Overview
Targacept, Inc. (Nasdaq: TRGT) is a world leader in the discovery and development of nicotinic acetylcholine receptor-based therapies for neurodegenerative, neuropsychiatric and gastrointestinal diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nassim Usman
Chief Financial Officer
Fletcher Payne
Chief Medical Officer
Howard Levy
VP - Bus. Development
Jeffrey Landau
VP - Manufacturing
Andrew Hetherington
Browse more venture capital transactions:
Prev: 3/18/2003: Cellzome AG venture capital transaction
Next: 3/24/2003: TeraXion venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs